- Allscripts Healthcare Solutions (NASDAQ:MDRX) initiated with an Outperform rating and an $8 (21% upside) price target at RBC.
- Aprea Therapeutics (NASDAQ:APRE) initiated with an Outperform rating and a $45 (35% upside) price target at Baird.
- Avita Medical (NASDAQ:RCEL) initiated with an Outperform rating and a $9 (44% upside) price target at Oppenheimer. Shares down 6% premarket.
- Catalent (NYSE:CTLT) initiated with an Outperform rating and a $65 (10% upside) price target at RBC.
- Catasys (NASDAQ:CATS) initiated with an Outperform rating and a $35 (18% upside) price target at RBC.
- HMS Holdings (NASDAQ:HMSY) initiated with a Sector Perform rating and a $27 (4% downside risk) price target at RBC.
- Health Catalyst (NASDAQ:HCAT) initiated with an Outperform rating and a $30 (17% upside) price target at RBC.
- Livongo Health (NASDAQ:LVGO) initiated with a Buy rating and a $55 (45% upside) price target at Benchmark. Initiated with an Outperform rating and a $45 price target at RBC.
- NeoGenomics (NASDAQ:NEO) initiated with an Overweight rating and a $33 (15% upside) price target at Stephens.
- NextGen Healthcare (NASDAQ:NXGN) initiated with a Sector Perform rating and an $11 (1% upside) price target at RBC.
- Phreesia (NYSE:PHR) initiated with a Sector Perform rating and a $21 (7% downside risk) price target at RBC.
- Relmada Therapeutics (NASDAQ:RLMD) initiated with a Buy rating and a $63 (78% upside) price target at Goldman Sachs.
- Tabula Rasa HealthCare (NASDAQ:TRHC) initiated with an Outperform rating and a $70 (17% upside) price target at RBC.
- Allergan (NYSE:AGN) downgraded to Hold with a $193 (3% upside) price target at SunTrust. Shares down 1% premarket.
- Charles River Labs (NYSE:CRL) downgraded to Hold with a $139 (4% downside risk) price target at Jefferies.
- Illumina (NASDAQ:ILMN) downgraded to Neutral with a $310 (4% downside risk) price target at Baird.
- Eli Lilly (NYSE:LLY) downgraded to Neutral with a $158 (flat) price target at UBS. Shares down 1% premarket.